Traumatic Brain Injury
Brain injury from physical trauma with lasting neurological effects. MSC therapy reduces neuroinflammation and promotes neuroplasticity.
Traumatic brain injury encompasses a spectrum of acute brain damage caused by external physical force — ranging from concussion and contusion to diffuse axonal injury and intracerebral hemorrhage. An estimated 69 million people experience TBI annually worldwide, with moderate-to-severe injuries producing lasting cognitive, motor, sensory, and behavioral deficits.
The secondary injury cascade — driven by neuroinflammation, excitotoxicity, oxidative stress, and blood-brain barrier disruption — extends damage well beyond the initial impact zone for days to weeks afterward. This secondary phase represents a critical therapeutic window that current standard care does not adequately address.
MSC therapy is being explored as a neuroprotective and neurorestorative strategy within this secondary injury window, as well as for patients in the chronic TBI phase seeking to improve persistent deficits.
MSCs administered in the subacute TBI phase (days to weeks after injury) distribute to the peri-lesional zone and secrete factors that suppress microglial activation, reduce blood-brain barrier permeability, decrease oxidative stress, and preserve axonal integrity. Published preclinical work demonstrates reduced lesion volume, improved white matter preservation, and functional recovery in treated animals.
Human clinical trials — including randomized controlled studies — have reported improvements in Rancho Los Amigos scale scores, Glasgow Outcome Scale-Extended (GOS-E), and cognitive battery performance in MSC-treated TBI patients compared with controls. Some studies have also used diffusion tensor imaging to document improved white matter tract integrity.
True Regen evaluates each TBI patient individually — considering time since injury, neuroimaging findings, current deficits, and rehabilitation status — to determine protocol eligibility and coordinate treatment with Regen Cord.
- Improved cognitive function and memory performance
- Better motor recovery and coordination
- Reduced neuroinflammatory markers
- Improved quality of life and independence measures
- Enhanced neuroplasticity and rehabilitation response
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.